Efficacy and safety of guaifenesin for upper back, neck, and shoulder pain: a Phase II proof-of-concept, multicenter, placebo-controlled, repeat-dose, parallel-group study.

J Pain Res · 2017 · PMC5367561 · PMID 28356767

Europe PMC DOI

hedged sentence

0.0523

closest p · 1.0× alpha

0.0523

boldest claim

The sentences

borderline significantP =0.0523so close (0.05 < p ≤ 0.1)

There was a significant difference between guaifenesin 1200 mg BID and placebo-1200 ( P =0.0211) for GATH and a borderline significant difference between these 2 groups for muscle relaxation ( P =0.0523).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.